Recruiting

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

I8H-MC-BDCL - ClinicalTrials.gov - NCT04450394

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
How long will I be in the trial?
The study will last about 33 weeks and may include up to 21 visits.
Email
Recruiting

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

I8H-MC-BDCL - ClinicalTrials.gov - NCT04450394

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
How long will I be in the trial?
The study will last about 33 weeks and may include up to 21 visits.
Email

Key Requirements

Age :

18-75

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18-75

Sex

All

Participants must

Participants must have type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with a stable dose of metformin in combination with a stable dose of a Dipeptidyl Peptidase IV (DPPIV) inhibitor and/or a Sodium-glucose co-transporter-2 (SGLT2) inhibitor) for at least 3 months prior to screening

Participants must have a HbA1c value of 7.0% to 9.5%, inclusive

Participants must have a body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m²), inclusive

Participants must NOT

Participants must not have type 1 diabetes mellitus or latent autoimmune diabetes

Participants must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening

Participants must not have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)

Participants must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease

Participants must not have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²

Participants must not have active or untreated cancer

Participants must not be on chronic (>14 days) systemic glucocorticoid therapy

Trial Summary

Conditions the trial is for

Adult Type 2 Diabetes

What the trial is testing?

LY3209590

Could I receive a Placebo?

no

Enrollment Goal

264

Trial Dates

July 2020 - September 2021

Trial Phase

2

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18-75

Sex

All

Participants must

Participants must have type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with a stable dose of metformin in combination with a stable dose of a Dipeptidyl Peptidase IV (DPPIV) inhibitor and/or a Sodium-glucose co-transporter-2 (SGLT2) inhibitor) for at least 3 months prior to screening

Participants must have a HbA1c value of 7.0% to 9.5%, inclusive

Participants must have a body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m²), inclusive

Participants must NOT

Participants must not have type 1 diabetes mellitus or latent autoimmune diabetes

Participants must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening

Participants must not have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)

Participants must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease

Participants must not have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²

Participants must not have active or untreated cancer

Participants must not be on chronic (>14 days) systemic glucocorticoid therapy

Trial Summary

Conditions the trial is for

Adult Type 2 Diabetes

What the trial is testing?

LY3209590

Could I receive a Placebo?

no

Enrollment Goal

264

Trial Dates

July 2020 - September 2021

Trial Phase

2

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Adult Type 2 Diabetes Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?